Cohort profile: The danish HIV cohort study

International Journal of Epidemiology

Volumn 38, Issue 5, 2009, Pages 1202-1206

  Obel, Niels ^a   Engsig, Frederik N ^a   Rasmussen, Line D ^b   Larsen, Mette V ^c   Omland, Lars H ^a   Sørensen, Henrik T ^d,e  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Copenhagen University Hospital ^*  (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COHORT ANALYSIS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DENMARK; FOLLOW UP; FUNDING; HEALTH CARE SYSTEM; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MORBIDITY; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RESEARCH SUBJECT; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DENMARK; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREVALENCE; PROSPECTIVE STUDIES;

EID: 70349853067     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyn192     Document Type: Article

References (24)

1. Bygbjerg IC. AIDS in a Danish surgeon (Zaire, 1976). Lancet 1983;1:925.
2. Gerstoft J, Malchow-Møller A, Bygbjerg I et al. Severe acquiret immunodeficiency in Euuropean homosexual men. Br Med J 1982;285 17-19.
3. Statistics Denmark. Available at www.statisitkbanken.dk (Accessed March 3, 2008).
4. Lohse N, Hansen ABE, Jensen-Fangel'S et al. Demographics of HIV-1 infection in Denmark: Results from The Danish HIV Cohort Study. Scand J Infect Dis 2005;37:338-43.
5. Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
6. Jensen-Fangel S, Pedersen L, Pedersen C et al. Low mortality in HIV-infected patients starting HAART in advance of immunological deterioration: A comparison with the general population. AIDS 2004;18:89-97.
7. Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: Consequences and perspectives. J Antimicrob Chemother 2007;60:461-63.
8. Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ ethnicity on the outcome of highly active antiretroviral therapy in HIV-1 infected patients in West Denmark. Clin Infect Dis 2002; 35:1541-48.
9. Lohse N, Kronborg G, Gerstoft J et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: A Danish population-based 6 years follow-up study. Clin Infect Dis 2006; 42:136-44.
10. Lohse N, Obel N, Kronborg G et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected. AIDS 2005; 20:815-22.
11. Lohse N, Jørgensen LB, Kronborg G et al. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Antiviral Ther 2007;12:909-17.
12. Lohse N, Obel N, Kronborg G et al. Declining prevalence of HIV infected individuals at risk of transmitting resistant HIV in Denmark during the period 1995-2003. Antiv Viral Ther 2006;11 591-600.
13. Weis N, Lindhardt BØ, Kronborg G et al. Impact of HCV co-infection on response to HAART and outcome in HIV-COHORT infected individuals: A nation-wide cohort study. Clin Infect Dis 2006; 42:1481-87.
14. Omland LH, Weis N, Skinhoj P et al. Impact of HBV coinfection on response to HAART and outcome in HIV-infected individuals: A nationwide cohort study. HIV Med 2008;9:300-6.
15. Hansen ABE, Gerstoft J, Kronborg G et al. Mortality in siblings of patients co-infected with HIV and hepatitis C virus. J Infect Dis 2007;195:230-35.
16. Hansen ABE, Lohse N, Gerstoft J et al. Cause-specific excess mortality in siblings of patients coinfected with HIV and hepatitis C virus. PLOS One 2007;2:e738.
17. Périard D, Telenti A, Sudre P et al. Atherogenic Dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-5.
18. Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med 2006;7 38-45.
19. Obel N, Thomsen HF, Kronborg G et al. Highly active antiretroviral therapy and hospitalization for ischemic heart disease in HIV-infected patients: A population-based cohort study. Clin Infect Dis 2007; 44:1625-31.
20. Rasmussen LD, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Obel N. Mortality after myocardial infarction in HIV-infected patients who have initiated HAART. AIDS 2007;21:873-75.
21. Fellay J, Shianna KV, Ge D et al. Identification of major determinants of the host control of HIV-1 through a whole-genome association study. Science 2007;317:944-47.
22. Pillay D, Bhaskaran K, Jurriaans S et al. CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006;20:21-28.
23. Rhee SY, Kantor R, Katzenstein DA et al. International Non Subtype B HIV-1 Working Group. HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. AIDS 2006;20:643-51.
24. Masquelier B, Bhaskaran K, Pillay D et al. CASCADE Collaboration. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005;40:505-11.